Literature DB >> 11502801

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

M B Toft-Nielsen1, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst.   

Abstract

To elucidate the causes of the diminished incretin effect in type 2 diabetes mellitus we investigated the secretion of the incretin hormones, glucagon-like peptide-1 and glucose- dependent insulinotropic polypeptide and measured nonesterified fatty acids, and plasma concentrations of insulin, C peptide, pancreatic polypeptide, and glucose during a 4-h mixed meal test in 54 heterogeneous type 2 diabetic patients, 33 matched control subjects with normal glucose tolerance, and 15 unmatched subjects with impaired glucose tolerance. The glucagon-like peptide-1 response in terms of area under the curve from 0-240 min after the start of the meal was significantly decreased in the patients (2482 +/- 145 compared with 3101 +/- 198 pmol/liter.240 min; P = 0.024). In addition, the area under the curve for glucose-dependent insulinotropic polypeptide was slightly decreased. In a multiple regression analysis, a model with diabetes, body mass index, male sex, insulin area under the curve (negative influence), glucose-dependent insulinotropic polypeptide area under the curve (negative influence), and glucagon area under the curve (positive influence) explained 42% of the variability of the glucagon-like peptide-1 response. The impaired glucose tolerance subjects were hyperinsulinemic and generally showed the same abnormalities as the diabetic patients, but to a lesser degree. We conclude that the meal-related glucagon-like peptide-1 response in type 2 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502801     DOI: 10.1210/jcem.86.8.7750

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  226 in total

1.  Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus.

Authors:  Jennifer Lee; Bethany P Cummings; Elizabeth Martin; James W Sharp; James L Graham; Kimber L Stanhope; Peter J Havel; Helen E Raybould
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-07       Impact factor: 3.619

2.  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

Authors:  Alberto Patriti; Enrico Facchiano; Annibale Donini
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 3.  Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.

Authors:  Priscila C Sala; Raquel S Torrinhas; Steven B Heymsfield; Dan L Waitzberg
Journal:  Obes Surg       Date:  2012-01       Impact factor: 4.129

Review 4.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 5.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

6.  Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.

Authors:  Sylvia H Jackson; Tonya S Martin; Jocelyn D Jones; David Seal; Frank Emanuel
Journal:  P T       Date:  2010-09

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  β-Cell dysfunction is associated with metabolic syndrome severity in adults.

Authors:  Steven K Malin; Stephen Finnegan; Ciaran E Fealy; Julianne Filion; Michael B Rocco; John P Kirwan
Journal:  Metab Syndr Relat Disord       Date:  2013-11-27       Impact factor: 1.894

9.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

10.  GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Authors:  Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  Clin Sci (Lond)       Date:  2014-08       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.